AIM logo
Alcohol in
Moderation
  • Home
  • Articles
  • Aim Digest
  • About AIM
  • AIM Council
Subscribe
Log in
  • All articles
  • All critiques
  • All-cause mortality& alcohol
  • Cancer& alcohol
    • Breast cancer
    • Colorectal cancers
    • Head and neck cancers
    • Lung cancer
    • Prostate cancer
  • Diabetes& alcohol
  • Heart& alcohol
    • Arrhythmia
    • Cardiovascular disease
    • Coronary heart disease
    • Cholesterol
    • Heart attack
    • Heart failure
    • Hypertension
  • Antioxidants& alcohol
  • Bone mineral density& alcohol
  • The brain& alcohol
    • Cognitive decline
  • General health& alcohol
  • J-shaped curve& alcohol
  • The kidneys& alcohol
  • The liver& alcohol
  • Mediterranean diet& alcohol
  • Moderate drinking
  • Old age& alcohol
    • Cognitive decline
  • Parkinsons' disease& alcohol
  • Arthritis& alcohol
  • Stroke
  • Women& alcohol
    • Breast cancer
    • Pregnancy
Choose a Topic
May 2026
Moderate drinking

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol-free and low-alcohol products in higher risk groups

Alcohol-free and low-alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high-income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol-related health problems should take a zero-tolerance approach to these alcohol-like products or encourage patients to try them. Academics argue that no/lo drinks may have an important role to play for people who drink at high-risk levels and those with alcohol use disorders (AUD) or alcohol-related liver disease (ARLD), particularly where debate and guidance related to treatment of these problems considers goals other than abstinence. The limited available evidence available suggests no/lo drinks may be useful in supporting attempts to reduce alcohol consumption or maintain abstinence among high-risk drinkers who do not have severe AUD or ARLD; however, they may also entail significant risks of relapse in those recovering from AUD. Further experimental and longitudinal studies are therefore needed, testing whether use of no/lo drinks can lead to, or support, reductions in alcohol consumption. In particular, there is a need for high-quality experimental studies to test whether exposure to and sustained use of no/lo drinks affects treatment and recovery outcomes. Evidence is also needed on which subgroups of AUD and ARLD patients would benefit or be at risk from use of either alcohol-free or low-alcohol drinks. Finally, guidance should recognise that many patients already use these products and that a zero-tolerance approach may alienate patients or erode trust in clinicians.
Source: J Holmes, CK Oldroyd, C Drummond, M Field, I Kersbergen, Allison MED. Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol-free and low-alcohol products in higher risk groups. Addiction. 2026 May;121(5):1036-1041.

doi.org/10.1111/add.70244
Drinking & You logo
Drinking & You
A global portal providing advice about responsible alcohol consumption, individual country government guidelines and your health.
Go to website
International Scientific Forum on Alcohol Research logo
International Scientific Forum on Alcohol Research
The International Scientific Forum on Alcohol Research (ISFAR) is a group of 45 specialist Professors and Medics who produce balanced and well researched analysis of emerging research papers alcohol and health.
Go to website

To receive notification of updates to the website, please subscribe here

Name(Required)

Topics

Harmful consumption

& alcohol

Healthy lifestyle

& alcohol

Genetics

& alcohol

Depression

& alcohol

Mental health

& alcohol

All-cause mortality

& alcohol

Cancer

& alcohol

Diabetes

& alcohol

Heart

& alcohol

Antioxidants

& alcohol

Bone mineral density

& alcohol

The brain

& alcohol

General health

& alcohol

Gut health

& alcohol

J-shaped curve

& alcohol

The kidneys

& alcohol

The liver

& alcohol

Mediterranean diet

& alcohol

Metabolic syndrome/weight

& alcohol

Moderate drinking

Old age

& alcohol

Parkinsons' disease

& alcohol

Arthritis

& alcohol

Stroke

& alcohol

Women

& alcohol

Latest articles

Reevaluating the alcohol–cancer link: Long-term cancer mortality outcomes in the REGARDS Study

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol-free and low-alcohol products in higher risk groups

Alcohol consumption and molecular subtypes of colorectal cancer: pooled observational and Mendelian randomization analyses

Alcohol consumption and the incidence of hyperuricemia in Japanese men and women

Alcohol-attributable cancer risk and burden estimates for Australia’s updated alcohol consumption guidelines

Aim Digest

September 2026

June 2026

May 2026

April 2026

February 2026

© Alcohol In Moderation, 2026.
Web design by Rubber Duckers
Close menu
  • Home
  • Articles
  • Aim Digest
  • About AIM
  • AIM Council
Subscribe
Log in
Close menu
  • All articles
  • All critiques
  • All-cause mortality& alcohol
  • Cancer& alcohol
    • ← Back
    • Breast cancer
    • Colorectal cancers
    • Head and neck cancers
    • Lung cancer
    • Prostate cancer
  • Diabetes& alcohol
  • Heart& alcohol
    • ← Back
    • Arrhythmia
    • Cardiovascular disease
    • Coronary heart disease
    • Cholesterol
    • Heart attack
    • Heart failure
    • Hypertension
  • Antioxidants& alcohol
  • Bone mineral density& alcohol
  • The brain& alcohol
    • ← Back
    • Cognitive decline
  • General health& alcohol
  • J-shaped curve& alcohol
  • The kidneys& alcohol
  • The liver& alcohol
  • Mediterranean diet& alcohol
  • Moderate drinking
  • Old age& alcohol
    • ← Back
    • Cognitive decline
  • Parkinsons' disease& alcohol
  • Arthritis& alcohol
  • Stroke
  • Women& alcohol
    • ← Back
    • Breast cancer
    • Pregnancy